ADVL1322 (VEG116731/PZP034X2203), A Phase II Study of Pazopanib (GW786034, NSC#737754) in Children, Adolescents and Young Adults with Refractory Solid Tumors

Protocol: 
AAAP3554
Phase: 
II

ADVL1322 (VEG116731/PZP034X2203), A Phase II Study of Pazopanib (GW786034, NSC#737754) in Children, Adolescents and Young Adults with Refractory Solid Tumors

Anti-angiogenic therapy via vascular endothelial growth factor blockade has been shown in several studies to be an effective cancer therapy. This is a two stage open label phase II trial of pazopanib in children, adolescents and young adults with recurrent or refractory solid tumors. Tumors of primary interest are rhabdomyosarcoma, non-rhabdomyosarcomatous soft tissue sarcoma and Ewing sarcoma. Secondary interest tumors include hepatoblastoma, neuroblastoma, and osteosarcoma. Patients will recieve pazopanib daily as an oral tablet or take powder for suspension. Patients will be monitored with clinical and laboratory observations for adverse effects. Response will be evaluated using appropriate imaging studies after the 2nd cycle of pazopanib, after the 4th cycle, and then every 3rd cycle thereafter. Pazopanib will be administered orally once a day as a tablet or as a suspension.

Are you Eligible? (Inclusion Criteria)

-At least 1 year and up to 18 years of age at the time of study entry.
-Patients must have one of the following types of cancer: a)
Rhabdomyosarcoma, b) Non-rhabdomyosarcomatous Soft Tissue Sarcoma (including
desmoplastic small round cell tumor), c) Ewing Sarcoma / Peripheral Primitive
Neuroectodermal Tumor (PNET), d) Osteosarcoma, e) Neuroblastoma (Measurable),
f) Neuroblastoma (Evaluable), g) Hepatoblastoma.
-Relapsed or refractory disease
-Patients must also meet all other eligibility criteria as outlined in the
study

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States